Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



FDA Says "No Way!" Market Says "Yeah, Baby!"

Don't let it get away!

Keep track of the stocks that matter to you.

Help yourself with the Fool's FREE and easy new watchlist service today.

The Food and Drug Administration's response wasn't exactly what investors in Amylin Pharmaceuticals (Nasdaq: AMLN  ) , Eli Lilly (NYSE: LLY  ) , and Alkermes (Nasdaq: ALKS  ) were looking for, but they'll take it. Amylin and Alkermes are both trading up more than 13% after the FDA rejected the once-weekly version of diabetes drug Byetta. The larger Eli Lilly, which isn't as dependent on one drug, was trading flat.

Why the positive response to the FDA saying that it wouldn't approve the drug at this time? Ten little words: "[T]here are no requests for new pre-clinical or clinical trials." Unlike being a little pregnant, it is possible to be a little rejected.

The companies highlighted just two issues that the FDA would like addressed. First, the Risk Evaluation and Mitigation Strategy (REMS) needs a little tweaking. Second, the FDA would like clarification about manufacturing of the drug, which will be called Bydureon if approved.

Amylin said it expects to respond to the FDA in a few weeks, and the only question now is whether the FDA will deem the response to be class 1 (with review likely finished in two months) or class 2 (review finished in six months). In the big picture, the difference of four months won't matter too much. But it would be nice to launch Bydureon sooner rather than later and not give Novo Nordisk's once-daily Victoza too much time to get established. Bydureon also has once-weekly competition behind it from Roche and another from GlaxoSmithKline (NYSE: GSK  ) and Human Genome Sciences (Nasdaq: HGSI  ) .

Merck (NYSE: MRK  ) , Bristol-Myers Squibb (NYSE: BMY  ) , and the rest of the companies with oral diabetes medications better start revving up their promotional activities. Byetta with its twice-daily injections was never able to compete very well, but Byduereon's once-weekly formulation should be a formidable rival. From the looks of things, the competition should start by year's end, if not sooner.

Listen to the wrong people and you'd think it was stupid to buy these stocks.

Motley Fool Rule Breakers is always on the hunt for hot drug stocks and other cutting-edge picks. Click here to see all of our latest discoveries with a free 30-day trial subscription.

Fool contributor Brian Orelli, Ph.D., doesn't own shares of any company mentioned in this article. Novo Nordisk is a former Global Gains pick. The Fool owns shares of GlaxoSmithKline and has a disclosure policy.

Read/Post Comments (4) | Recommend This Article (7)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On March 15, 2010, at 4:50 PM, parsonez57 wrote:

    The drug was not rejected! How is "additional clinical information would not be needed in its review of Bydureon, an extended-release, once-weekly medication designed to control glycemic levels in type 2 diabetes patients" a rejection? This is a foolish mistake to put this information in the news.

  • Report this Comment On March 15, 2010, at 4:54 PM, parsonez57 wrote:

    Wrong about Amln. Drug was NOT rejected. Bad article fools. FDA just needs labeling information. No more tests are needed for the drug.

  • Report this Comment On March 15, 2010, at 5:03 PM, TMFBiologyFool wrote:

    Just because the FDA uses the euphemism "complete response letter" to make everyone feel better, doesn't mean investors need to.

    The companies asked if they could market the drug. The FDA said, not yet. That's a rejection in my book.

    -Brian Orelli

  • Report this Comment On March 15, 2010, at 5:16 PM, TMFBiologyFool wrote:

    Just because the FDA uses the euphemism "complete response letter" to make everyone feel better, doesn't mean investors need to.

    The companies asked the FDA if they could market the drug. The FDA said, not yet. That's a rejection in my book.

    -Brian Orelli

Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 1134966, ~/Articles/ArticleHandler.aspx, 2/14/2016 12:16:23 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Brian Orelli

Dr. Orelli is a Senior Biotech Specialist. He has written about biotech, pharmaceutical, and medical device companies for The Motley Fool since 2007.

Today's Market

updated 1 day ago Sponsored by:
DOW 15,973.84 313.66 2.00%
S&P 500 1,864.78 35.70 1.95%
NASD 4,337.51 70.68 1.66%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

2/12/2016 3:59 PM
ALKS $32.45 Up +1.26 +4.04%
Alkermes, Inc. CAPS Rating: ***
AMLN.DL $0.00 Down +0.00 +0.00%
Amylin Pharmaceuti… CAPS Rating: **
LLY $71.27 Down -0.15 -0.21%
Eli Lilly & Co. CAPS Rating: ****
BMY $60.20 Up +0.68 +1.14%
Bristol-Myers Squi… CAPS Rating: ****
GSK $39.76 Up +0.61 +1.56%
GlaxoSmithKline CAPS Rating: ****
HGSI.DL $0.00 Down +0.00 +0.00%
Human Genome Scien… CAPS Rating: **
MRK $49.03 Up +0.18 +0.37%
Merck & Co., Inc. CAPS Rating: ****